Ovarian Cancer

CHICAGO — Intermittent relacorilant plus nab-paclitaxel demonstrated an OS benefit among women with recurrent platinum-resistant/refractory ovarian cancer compared with nab-paclitaxel alone.

CHICAGO — Rucaparib monotherapy significantly prolonged PFS compared with placebo in the first-line maintenance setting among women with advanced ovarian cancer, regardless of BRCA mutation and homologous recombination deficiency status.

SAN DIEGO — In this video, Rochelle F. Andreotti, MD, a professor of clinical radiology, radiological sciences and OB/GYN at Vanderbilt University Medical Center, recaps her endowed lecture on adnexal mass evaluation.

The FDA granted fast track designation to ofranergene obadenovec in combination with paclitaxel for treatment of platinum-resistant ovarian cancer.

Break Through Cancer will award $50 million in grants designed to maximize interdisciplinary collaboration among researchers at five top cancer centers.

Early data from a phase 1 trial showed encouraging clinical activity for an investigational chimeric antigen receptor T-cell therapy alone or in combination with an amplifying mRNA vaccine for patients with solid tumors.

Rucaparib monotherapy significantly extended PFS compared with placebo as first-line maintenance treatment for women with ovarian cancer, according to topline data from the randomized phase 3 ATHENA-MONO trial.

Women with mitogen-activated protein kinase-mutated low-grade serous ovarian/peritoneal carcinoma experienced significantly longer PFS and OS compared with women without these mutations, according to study results.

Mirvetuximab soravtansine demonstrated efficacy and tolerability in patients with platinum resistant ovarian cancer, according to phase 3 clinical data presented at Society of Gynecologic Oncology Annual Meeting on Women’s Cancer.

Folate receptor alpha expression predicted benefit from mirvetuximab soravtansine in platinum-resistant high-grade serous epithelial ovarian, primary peritoneal or fallopian tube cancers, according to a results of the phase 3 SORAYA study.